 So my name is Maxim Zasville. I work for Health Canada for the Pharmaceutical Drug Directorate. Health Canada is the regulatory authority in Canada for the approval of new drugs, new therapies for all therapeutic areas. And my group, I lead a group of reviewers that work on improving new therapies for cancer and hematology. So Health Canada has a framework for which we basically establish benefit-risk uncertainty profile for every drug. As a first-fold, we look at patient-reported outcomes to establish the tolerability of a new therapy and also assess symptoms for patients' due experience. So that's the first thing we try to measure and establish. As a second-fold, we certainly also look at whether we can use patient-reported outcomes for treatment benefit. That takes a little bit more level of predetermination and preparation, but that's certainly something that can be achieved increasingly in cancer. What we hope CISACWAL will achieve is to increase certainly harmonization. I think that as a regulator we oftentimes face situations where different regulators have different recommendations for the sponsors. I think for a middle-sized regulator like Health Canada, we do appreciate the possibility of harmonizing requirements or at least agreeing to a minimum number of basic rules to guide the design, the collection analysis and reporting of patient-reported outcomes. The challenges we often see are the same for I think all parties involved in cancer clinical trials. You want to minimize missing data, you want to be able to handle those missing data correctly, and you want to have robust PROs to guide your decision-making. That's I think one of the big goals and big achievements that CISACWAL will hopefully get to address. For patients, definitely what we're looking at is that improving the standards. What we hope is that we're going to have increasing quality of data by maximizing the quality of data in terms of what we hope is that we're going to increasingly be able to rely and use them proactively to make our decision-making. And basically the goal especially in cancer is that you want to get the therapies as fast as possible on the market. And I think the more data we have, the highest quality of data we have, the easier it is for us to run those benefit-risk uncertainty profiles and take decisions to make therapy available for cancer patients.